Journal of Jilin University(Medicine Edition) ›› 2025, Vol. 51 ›› Issue (6): 1618-1629.doi: 10.13481/j.1671-587X.20250617
• Research in clinical medicine • Previous Articles Next Articles
Limei WEN1,2,Yali GUO2,3,Wenmei MA4,Taotao XUE2,3,Ruoyu GENG2,3,Chong MA2,3,Xinhong ZHANG2,3,Jianhua YANG1,2(
)
Received:2024-12-26
Accepted:2025-02-17
Online:2025-11-28
Published:2025-12-15
Contact:
Jianhua YANG
E-mail:yjh-yfy@163.com
CLC Number:
Limei WEN,Yali GUO,Wenmei MA,Taotao XUE,Ruoyu GENG,Chong MA,Xinhong ZHANG,Jianhua YANG. Bioinformatic analysis of TCGA database based on INPP4B gene expression in hepatocellular carcinoma and its experimental validation[J].Journal of Jilin University(Medicine Edition), 2025, 51(6): 1618-1629.
Tab.1
Univariate and multivariate Cox regression analysis"
| Characteristics | Total case | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |||
| T stage | 370 | |||||
| T1-T2 | 277 | Reference | ||||
| T4-T3 | 93 | 2.598 (1.826-3.697) | <0.001 | 1.606 (0.212-12.182) | 0.647 | |
| N stage | 258 | |||||
| N0 | 254 | Reference | ||||
| N1 | 4 | 2.029 (0.497-8.281) | 0.324 | - | - | |
| M stage | 272 | |||||
| M0 | 268 | Reference | ||||
| M1 | 4 | 4.077 (1.281-12.973) | 0.017 | 1.447 (0.339-6.166) | 0.618 | |
| Pathologic stage | 349 | |||||
| Ⅰ-Ⅱ | 259 | Reference | ||||
| Ⅲ-Ⅳ | 90 | 2.504 (1.727-3.631) | <0.001 | 1.291 (0.171-9.743) | 0.804 | |
| Tumor status | 354 | |||||
| Tumor free | 202 | Reference | ||||
| With tumor | 152 | 2.317 (1.590-3.376) | <0.001 | 2.706 (1.616-4.531) | <0.001 | |
| Gender | 373 | |||||
| Female | 121 | Reference | ||||
| Male | 252 | 0.793 (0.557-1.130) | 0.200 | - | - | |
| Race | 361 | |||||
| Asian | 159 | Reference | ||||
| Black or African American | 17 | 1.585 (0.675-3.725) | 0.290 | - | - | |
| White | 185 | 1.323 (0.909-1.928) | 0.144 | - | - | |
| Age (year) | 373 | |||||
| ≤60 | 177 | Reference | ||||
| >60 | 196 | 1.205 (0.850-1.708) | 0.295 | - | - | |
| Weight (kg) | 345 | |||||
| ≤70 | 184 | Reference | ||||
| >70 | 161 | 0.941 (0.657-1.346) | 0.738 | - | - | |
| Height (cm) | 340 | |||||
| <170 | 201 | Reference | ||||
| ≥170 | 139 | 1.232 (0.849-1.788) | 0.272 | - | - | |
| BMI (kg·m-2) | 336 | |||||
| ≤25 | 177 | Reference | ||||
| >25 | 159 | 0.798 (0.550-1.158) | 0.235 | - | - | |
| Residual tumor | 344 | |||||
| R0 | 326 | Reference | ||||
| R1 | 17 | 1.448 (0.705-2.972) | 0.313 | 1.218 (0.439-3.378) | 0.704 | |
| R2 | 1 | 11.749 (1.595-86.516) | 0.016 | - | - | |
| Histologic grade | 368 | |||||
| G1-G2 | 233 | Reference | ||||
| G3-G4 | 135 | 1.091 (0.761-1.564) | 0.636 | - | - | |
| AFP(μg·L-1) | 279 | |||||
| ≤400 | 215 | Reference | ||||
| >400 | 64 | 1.075 (0.658-1.759) | 0.772 | - | - | |
| Prothrombin time (s) | 296 | |||||
| ≤4 | 207 | Reference | ||||
| >4 | 89 | 1.335 (0.881-2.023) | 0.174 | - | - | |
| Adjacent hepatic tissue inflammation | 236 | |||||
| None | 118 | Reference | ||||
| Mild | 101 | 1.204 (0.723-2.007) | 0.476 | - | - | |
| Severe | 17 | 1.144 (0.447-2.930) | 0.779 | - | - | |
| Albumin (g·dL-1) | 299 | |||||
| <35 | 69 | Reference | ||||
| ≥35 | 230 | 0.897 (0.549-1.464) | 0.662 | - | - | |
| Child-Pugh grade | 240 | |||||
| A | 218 | Reference | ||||
| B | 21 | 1.595 (0.757-3.361) | 0.219 | - | - | |
| C | 1 | 2.138 (0.294-15.544) | 0.453 | - | - | |
| Fibrosis ishak score | 214 | |||||
| 0-1/2 | 106 | Reference | ||||
| 3/4-5/6 | 108 | 0.740 (0.445-1.232) | 0.247 | - | - | |
| INPP4B | 373 | |||||
| Low expression | 187 | Reference | ||||
| High expression | 186 | 0.781 (0.552-1.105) | 0.163 | - | - | |
| [1] | VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. |
| [2] | VILLANUEVA A. Hepatocellular carcinoma. reply[J]. N Engl J Med, 2019, 381(1): e2. |
| [3] | MIDORIKAWA Y, TAKAYAMA T, HIGAKI T, et al. Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy[J]. Jpn J Clin Oncol, 2016, 46(12): 1102-1107. |
| [4] | KHEMLINA G, IKEDA S, KURZROCK R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies[J]. Mol Cancer, 2017, 16(1): 149. |
| [5] | 孙 颖, 丁 焕, 黎晓晴, 等. 转染INPP4B基因对三阴性乳腺癌细胞株MDA-MB-231增殖的影响[J]. 山东大学学报(医学版), 2013, 51(12): 41-45. |
| [6] | 岳 杰, 于振涛. 转移性食管癌分子靶向治疗的研究进展[J]. 中国肿瘤临床, 2016, 43(4): 170-172. |
| [7] | Hamila S A, Ooms L M, Rodgers S J, et al. The INPP4B paradox: Like PTEN, but different[J]. Adv Biol Regul, 2021, 82: 100817. |
| [8] | TANG W D, YANG L W, YANG T Y, et al. INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma[J]. Onco Targets Ther, 2019, 12: 3491-3507. |
| [9] | 张 冉, 逄瑷博, 靖 彧. 基于TCGA探讨急性髓系白血病患者miR-363表达与其临床特征及靶基因的关系[J]. 标记免疫分析与临床, 2023, 30(8): 1402-1406. |
| [10] | 杨 玺. 基于TCGA数据库构建恶性胸膜间皮瘤miRNA和基因预后模型及其生物信息学分析[D]. 大理: 大理大学, 2023. |
| [11] | 朱翠雯, 马甜甜, 段怡平, 等. 基于TCGA数据库分析DDX27在肝细胞癌中的预后价值[J]. 分子诊断与治疗杂志, 2023, 15(4): 549-553. |
| [12] | MA J Y, HUANG L J, HU D, et al. The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?[J]. J Exp Clin Cancer Res, 2021, 40(1): 327. |
| [13] | ZHOU G, WANG J P, ZHAO M, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation[J]. Mol Cell, 2014, 54(6): 960-974. |
| [14] | YIN G Z, JIA S Y, ZHANG Y J, et al. YAP1-activated ZNF131 promotes hepatocellular carcinoma cell proliferation through transcriptional regulation of PAIP1[J]. Arch Biochem Biophys, 2024, 754: 109921. |
| [15] | 张洋洋. INPP4B和PTEN蛋白在肝细胞癌中的表达及其意义[D]. 郑州: 郑州大学, 2014. |
| [16] | 王 湘, 张 森, 韩科研, 等. 苦参碱衍生物ZS10基于PI3K/AKT信号通路诱导人肝癌细胞BEL-7402凋亡[J]. 中国药理学通报, 2023, 39(1): 116-124. |
| [17] | SUN Y, ZHANG H, MENG J P, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway[J]. Cell Rep, 2022, 40(7): 111194. |
| [18] | 吴友亮. INPP4B在胃癌和胆囊癌中的临床意义及机制研究[D]. 合肥: 安徽医科大学, 2022. |
| [19] | HAN L, CHEN S, DU S Y. Role of inositol polyphosphate-4-phosphatase type II in oncogenesis of digestive system tumors[J]. World J Gastrointest Oncol, 2023, 15(10): 1706-1716. |
| [20] | CAO Y Y, JIAO N L, SUN T T, et al. CXCL11 correlates with antitumor immunity and an improved prognosis in colon cancer[J]. Front Cell Dev Biol, 2021, 9: 646252. |
| [21] | FU Y J, LIU S S, ZENG S, et al. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 396. |
| [22] |
CHEW V, LAI L Y, PAN L, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J]. Proc Natl Acad Sci USA, 2017, 114(29): E5900-E5909. DOI:10.1073/pnas.1706559114
doi: 10.1073/pnas.1706559114 |
| [23] | 李秀勤, 施章时, 伍 亮, 等. 胃癌外泌体lncRNA MM2P诱导STAT6磷酸化而促进M2型巨噬细胞极化[J]. 胃肠病学和肝病学杂志, 2022, 31(3): 304-309. |
| [24] | XU J X, WU X Y, CHEN J L, et al. A TP53-associated metabolic gene signature for the prediction of overall survival and therapeutic responses in hepatocellular carcinoma[J]. J Radiat Res Appl Sci, 2023, 16(2): 100552. |
| [25] | GUO W, YAO X H, LAN S Y, et al. Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P53/FoxO signaling axis[J]. Chin Med, 2022, 17(1): 76. |
| [26] | ZHANG X, WU Z X, PENG Y H, et al. Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients[J]. Biomed Res Int, 2021, 2021: 6651397. |
| [27] | XIE B H, HE X, HUA R X, et al. miR-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma[J]. Cancer Biomark, 2016, 16(3): 405-413. |
| [1] | Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780. |
| [2] | Xiaohui LIANG,Wenna LIU,Jianbo ZHAO. Bioinformatic analysis on PAQR3 expression in hepatocellular carcinoma and its correlations with T lymphocyte infiltration, immune checkpoint genes, and patient survival [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 781-790. |
| [3] | Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409. |
| [4] | Jiaxin WANG,Junwen MAO,Xuan ZHANG. Expression of natural autoantibodies against apoptosis inhibitory genes in plasma of patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 228-235. |
| [5] | Han LIN,Qiuyan YANG,Jieyue ZHONG,Bolun CHEN,Wangxia TONG. Improvement effect of cordycepin on ferroptosis in HepG2 cells induced by RSL3 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 576-589. |
| [6] | Xiaoyan WANG,Xuelian LI,Bin LIANG,Wenfei TIAN,Hailin MA,Zhijing MO. Analysis on relationship between CALU and prognosis of hepatocellular carcinoma patients and its mechanism based on transcriptome and single cell sequencing data [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 447-459. |
| [7] | Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015. |
| [8] | Jinlian LI,Lanzhen HUANG,Xishi HUANG,Kangzhi LI,Jiali JIANG,Miaomiao ZHANG,Qunying WU. Bioinformatics analysis on key genes related to prognosis, diagnosis, and immune cell infiltration of hepatocellular carcinoma and their potential therapeutic drugs [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1062-1075. |
| [9] | Xiaoyan WANG,Hao ZHANG,Zehao GUO,Jun CAO,Zhijing MO. Screening of UBE2S interacting protein and construction of prognostic model in hepatocellular carcinoma [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 168-177. |
| [10] | Xiaopeng YU,Renyi YANG,Zuomei HE,Puhua ZENG. Establishment and validation of nomogram of cancer specific survival of patients with hepatocellular carcinoma with negative alpha fetoprotein based on SEER Database [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 188-197. |
| [11] | Yong DONG,Lingyao XU,Jing HUA,Han LIANG,Dongya LIU,Junbo ZHAO,Zhenglu SUN,Cheng CHENG,Shutang WEI. Effect of macrophage exosomal lncRNA HULC on migration, invasion,and metastasis of hepatocellular carcinoma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1217-1226. |
| [12] | Wenjun DENG,Liantao HU,Binnan ZHAO,Xinyu DONG,Xuebin LI,Jie LI,Xinyan YANG,Xiaoli GUO,Yue LI,Yikun QU,Weiqun WANG. Effect of CXC chemokine ligand 10 on proliferation and migration of hepatocellular carcinoma SMMC-7721 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1227-1233. |
| [13] | Yaqi XU,Yanyu WANG,Wenjing ZHANG,Mei HAN,Huaxia MU,Xi YANG,Weixiao BU,Zikun TAO,Yujia KONG,Fuyan SHI,Suzhen WANG. Bioinformatics analysis on screening of key genes of hepatitis B virus-related hepatocellular carcinoma and its relationship with prognosis [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1243-1252. |
| [14] | Yiming ZHAO,Haiyang XU. Bioinformatics analysis on related genes and candidate pathways of glioblastoma multiforme [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1280-1289. |
| [15] | Yuanyuan LIANG,Song ZHAO,Jing HU,Ni AN,Yanlu WEI,Rongjian SU. Effect of motesanib combined with EZH2 inhibitor GSK126 on proliferation and apoptosis of liver cancer Huh7 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(4): 896-904. |
|